Meta-analysis confirms CBD effectively reduces seizures in three pediatric epilepsy syndromes | Research

The takeaway

Pooled analysis of 6 RCTs found CBD (Epidiolex) more than doubled the odds of 50% or greater seizure reduction across Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.

Pediatric neurologists, parents of children with refractory epilepsy, and epilepsy researchers.

CBD more than doubled odds of 50%+ seizure reduction (OR=2.45, p<0.01)

What the researchers found

CBD treatment was significantly more effective than placebo (OR=2.45, 95% CI: 1.81-3.32). Subgroup analysis showed benefit in all three syndromes: Dravet (OR=2.26), Lennox-Gastaut (OR=2.98), and tuberous sclerosis complex (OR=1.99). Higher adverse event rates were seen with CBD, especially with clobazam co-therapy.

Why it matters

Refractory epilepsy in children is devastating and treatment options are limited. This meta-analysis strengthens the evidence base for CBD as both standalone and adjunct therapy across the three approved indications.

The numbers in context

6 RCTs included. Pooled OR for 50%+ seizure reduction: 2.45 (p<0.01). By syndrome: Dravet 2.26, LGS 2.98, TSC 1.99. Adverse events increased (OR=1.81), serious adverse events (OR=2.86). Common side effects: diarrhea, somnolence, sedation.

How the study worked

Systematic review and meta-analysis of 6 RCTs meeting eligibility criteria from 1,183 screened articles. All studies used pharmaceutical-grade oral CBD (Epidiolex) at 10-50 mg/kg/day for up to 16 weeks. Subgroup analyses by syndrome and clobazam co-therapy.

What this study cannot tell us

Only 6 RCTs available. All used one product (Epidiolex) at specific doses. Treatment duration limited to 16 weeks. Clobazam interaction complicates interpretation of whether CBD alone or the CBD-clobazam combination drives efficacy. Increased serious adverse events warrant careful monitoring.

How to read the evidence

Meta-analysis of 6 low-risk-of-bias RCTs. High-quality evidence for the approved indications, though limited to one pharmaceutical product.

When this study was published

Published 2023.

The bigger picture

CBD for pediatric epilepsy is one of the most well-studied cannabinoid medical applications. This meta-analysis reinforces that the benefits are real, while also highlighting the importance of managing side effects, particularly the drug interaction with clobazam.

Questions still open

How much of the seizure reduction is attributable to the CBD-clobazam interaction vs. CBD alone? What are the optimal long-term dosing strategies beyond 16 weeks?

Common questions

How effective is CBD for childhood epilepsy?

In this meta-analysis, children receiving CBD were more than twice as likely to achieve 50% or greater seizure reduction compared to placebo across three difficult-to-treat epilepsy syndromes. The strongest effect was seen in Lennox-Gastaut syndrome (OR=2.98).

What are the risks of CBD for epilepsy?

CBD increased the odds of adverse events (OR=1.81) and serious adverse events (OR=2.86) compared to placebo. The most common side effects were diarrhea, somnolence, and sedation. The interaction between CBD and clobazam (a common co-prescribed medication) contributed significantly to both increased efficacy and side effects.

Read the original research

Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.

Experimental neurology, 359, 114238

View on PubMed ↗Publisher’s paper ↗

Citation

Talwar, Ashna; Estes, Emily; Aparasu, Rajender; Reddy, Doodipala Samba. (2023). Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.. Experimental neurology, 359, 114238. https://doi.org/10.1016/j.expneurol.2022.114238